REFERENSI

Alcantara, K. M. M. and Garcia, R. L. (2018) 'MicroRNA-92a negatively regulates neurofibromin 2 and inhibits its tumor suppressive function', *bioRxiv*, p. 249177. doi: 10.1101/249177.

Almefty, R., Haddad, G. F. and Al-mefty, O. (2017) 'Meningiomas', in *Youmans and Winn Neurological Surgery*. 7th edn. Philadelphia: Elsevier, pp. 1107–1132. doi: 10.1016/B978-0-323-28782-1.00147-7.

Alruwaili, A. A. and Jesus, O. De (2021) 'Meningioma', *CyberKnife Stereotactic Radiosurgery: Brain*, 1, pp. 141–154. Available at: https://www.ncbi.nlm.nih.gov/books/NBK560538/ (Accessed: 8 October 2021).

Ammirati, M. and Lamki, T. (2017) 'Overview of Skull Base Tumors', in *Youmans and Winn Neurological Surgery*. 7th edn. Philadelphia: Elsevie, pp. 1222–1242.

Ardern-Holmes, S., Fisher, G. and North, K. (2017) 'Neurofibromatosis Type 2', *Journal of child neurology*, 32(1), pp. 9–22. doi: 10.1177/0883073816666736.

Bassiri, K. *et al.* (2017) 'Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target', *EBioMedicine*, 16, p. 76. doi: 10.1016/J.EBIOM.2017.01.020.

Brunner, E. C. *et al.* (2006) 'Altered expression of beta-catenin/E-cadherin in meningiomas', *Histopathology*, 49(2), pp. 178–187. doi: 10.1111/J.1365-2559.2006.02440.X.

Buerki, R. A. *et al.* (2018) 'An overview of meningiomas', *Future Oncology*, 14(21), pp. 2161–2177. doi: 10.2217/fon-2018-0006.

Cooper, J. and Giancotti, F. G. (2014) 'Molecular insights into NF2/Merlin tumor suppressor function', *FEBS Letters*, 588(16), pp. 2743–2752. doi: 10.1016/J.FEBSLET.2014.04.001.

Dirks, M. S. *et al.* (2012) 'Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors: Clinical article', *Journal of Neurosurgery*, 117(1), pp. 109–117. doi: 10.3171/2012.3.JNS111649.

Fathi, A.-R. and Roelcke, U. (2013) 'Meningioma', *Current Neurology and Neuroscience Reports 2013 13:4*, 13(4), pp. 1–8. doi: 10.1007/S11910-013-0337-4.

Goutagny, S. *et al.* (2012) 'Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: Clinical, radiological, and molecular features', *Neuro-Oncology*, 14(8), pp. 1090–1096. doi: 10.1093/neuonc/nos129.

Goutagny, S. and Kalamarides, M. (2010) 'Meningiomas and neurofibromatosis', *Journal of neuro-oncology*, 99(3), pp. 341–347. doi: 10.1007/S11060-010-0339-X.

Huntoon, K., Toland, A. and Dahiya, S. (2020) 'Meningioma: A Review of Clinicopathological and Molecular Aspects', *Frontiers in oncology*, 10. doi: 10.3389/FONC.2020.579599.

James, M. F. *et al.* (2008) 'Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth', *Neurobiology of disease*, 29(2), p. 278. doi: 10.1016/J.NBD.2007.09.002.

Kemenkes (2017) 'Panduan Nasional Pelayanan Kesehatan Tumor Otak'. Jakarta, p. 92.

Khoshnevisan, A. *et al.* (2019) 'Demographic, Clinical and Therapeutic Effects of Intracranial Meningioma', *Biomed J Sci & Tech Res*, 23(1). doi: 10.26717/BJSTR.2019.23.003839.

Kim, B. S. *et al.* (2022) 'Multiple craniospinal tumors in a pediatric patient with neurofibromatosis type 2: a case report', *Child's Nervous System*, 1, pp. 1–5. doi: 10.1007/S00381-022-05531-6/FIGURES/4.

Lee, S. *et al.* (2019) 'The role of merlin/NF2 loss in meningioma biology', *Cancers*, 11(11), pp. 1–14. doi: 10.3390/cancers11111633.

Look, A. and Lonser, R. R. (2020) *Inherited genetic syndromes and meningiomas*. 1st edn, *Handbook of Clinical Neurology*. 1st edn. Elsevier B.V. doi: 10.1016/B978-0-12-804280-9.00007-X.

Magill, S. T. *et al.* (2018) 'Relationship between tumor location, size, and WHO grade in meningioma', *Neurosurgical Focus*, 44(4). doi: 10.3171/2018.1.FOCUS17752.

Maître, J. L. and Heisenberg, C. P. (2013) 'Three Functions of Cadherins in Cell Adhesion', *Current Biology*, 23(14), p. R626. doi: 10.1016/J.CUB.2013.06.019.

Maiuri, F. *et al.* (2019) 'WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma', *Acta neurochirurgica*, 161(12), pp. 2553–2561. doi: 10.1007/S00701-019-

04084-Z.

Miller, J. L. and Grant, P. A. (2013) 'The Role of DNA Methylation and Histone Modifications in Transcriptional Regulation in Humans', *Sub-cellular biochemistry*, 61, p. 289. doi: 10.1007/978-94-007-4525-4_13.

Noorolyai, S. *et al.* (2019) 'The relation between PI3K/AKT signalling pathway and cancer', *Gene*, 698, pp. 120–128. doi: 10.1016/J.GENE.2019.02.076.

Nugraheni, N. P. L. (2018) *Tugas Akhir Identifikasi Penyakit Meningioma pada Citra Mri Menggunakan Metode Segmentasi Citra Klaster K-Means*. Universitas Katolik Parahyangan.

Ogasawara, C., Philbrick, B. D. and Adamson, D. C. (2021) 'Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions', *Biomedicines*, 9(3). doi: 10.3390/BIOMEDICINES9030319.

Ostrom, Q. T. *et al.* (2016) 'CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013', *Neuro-Oncology*, 18(Suppl 5), p. v1. doi: 10.1093/NEUONC/NOW207.

Oyem, P. C. *et al.* (2022) 'Natural history and volumetric analysis of meningiomas in neurofibromatosis type 2', *Neurosurgical focus*, 52(5), pp. 1–6. doi: 10.3171/2022.2.FOCUS21779.

Pavelin, S. *et al.* (2013) 'The Significance of Immunohistochemical Expression of', *Appl Immunohistochem Mol Morphol*, 00(00), pp. 1–4.

Petrilli, A. M. and Fernández-Valle, C. (2016) 'Role of Merlin/NF2 Inactivation in Tumor Biology', *Oncogene*, 35(5), p. 537. doi: 10.1038/ONC.2015.125.

Pham, L. and Wang, J. (2021) 'Meningioma', in *Ferri's Clinical Advisor 2022*. Philadelphia: Elsevier, pp. 967–968. doi: 10.1016/B978-0-323-75570-2.00574-9.

Shen, Y. *et al.* (2009) 'Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas', *BMC Medical Genomics*, 2, p. 42. doi: 10.1186/1755-8794-2-42.

Supartoto, A. *et al.* (2019) 'Relationships between neurofibromatosis-2, progesterone receptor expression, the use of exogenous progesterone, and risk of orbitocranial meningioma in females', *Frontiers in Oncology*, 9(JAN), p. 651. doi: 10.3389/FONC.2018.00651/BIBTEX.

Tamura, R. (2021) 'Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis', *International Journal of Molecular Sciences*, 22(11). doi: 10.3390/IJMS22115850.

Waldt, N. *et al.* (2020) 'Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development', *Journal of the neurological sciences*, 408. doi: 10.1016/J.JNS.2019.116553.

Wedemeyer, M. A. *et al.* (2022) 'Epigenetic dysregulation in meningiomas', *Neuro-Oncology Advances*, 4(1). doi: 10.1093/NOAJNL/VDAC084.

Wei, J. W. *et al.* (2017) 'Non-coding RNAs as regulators in epigenetics (Review)', *Oncology Reports*, 37(1), pp. 3–9. doi: 10.3892/OR.2016.5236/HTML.

Wöhrer, A. (2013) 'Epidemiology of Meningioma', *European Association NauroOncology Magazine*, 3(3), pp. 95–96. Available at: www.kup.at/ (Accessed: 26 November 2021).

Yang, C. *et al.* (2011) 'Missense mutations in the NF2 gene result in the quantitative loss of merlin protein and minimally affect protein intrinsic function', *Proceedings of the National Academy of Sciences*, 108(12), pp. 4980–4985. doi: 10.1073/PNAS.1102198108.

Yao, Q., Chen, Y. and Zhou, X. (2019) 'The roles of microRNAs in epigenetic regulation', *Current Opinion in Chemical Biology*, 51, pp. 11–17. doi: 10.1016/J.CBPA.2019.01.024.